The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
University of California, Los Angeles · Cancer Trials Ireland · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,906
total citations
- FWCI
- 135.00
- Percentile
- 100%
- References
- 23
Citations per year
Authors
18- RSRichard S. Finn
University of California, Los Angeles
- JCJohn Crown
Cancer Trials Ireland
- ILIstván Láng
National Institute of Criminology
- KBKatalin Boér
Szent János Kórház
- IMIgor M Bondarenko
Dnipro State Medical University
Topics & keywords
Topics
Keywords
- Palbociclib
- Letrozole
- Medicine
- Oncology
- Breast cancer
- Internal medicine
- Clinical endpoint
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.